SG11201407599SA - Oligonucleotide chelate complex-polypeptide compositions and methods - Google Patents

Oligonucleotide chelate complex-polypeptide compositions and methods

Info

Publication number
SG11201407599SA
SG11201407599SA SG11201407599SA SG11201407599SA SG11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA
Authority
SG
Singapore
Prior art keywords
international
quebec
rule
montreal
applicant
Prior art date
Application number
SG11201407599SA
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407599S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of SG11201407599SA publication Critical patent/SG11201407599SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
SG11201407599SA 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods SG11201407599SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
SG11201407599SA true SG11201407599SA (en) 2014-12-30

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407599SA SG11201407599SA (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Country Status (34)

Country Link
US (1) US9492506B2 (enExample)
EP (1) EP2849798B1 (enExample)
JP (1) JP2015517504A (enExample)
KR (1) KR102068109B1 (enExample)
CN (1) CN104349793B (enExample)
AU (1) AU2013262416B2 (enExample)
BR (1) BR112014028654A2 (enExample)
CA (1) CA2873529C (enExample)
CL (1) CL2014003134A1 (enExample)
CO (1) CO7131387A2 (enExample)
CR (1) CR20140527A (enExample)
CY (1) CY1124345T1 (enExample)
DK (1) DK2849798T3 (enExample)
DO (1) DOP2014000264A (enExample)
EA (1) EA035967B1 (enExample)
EC (1) ECSP14027694A (enExample)
ES (1) ES2873844T3 (enExample)
HR (1) HRP20210840T1 (enExample)
HU (1) HUE054875T2 (enExample)
IL (1) IL235548B (enExample)
LT (1) LT2849798T (enExample)
MX (1) MX346239B (enExample)
MY (1) MY168778A (enExample)
NZ (1) NZ703095A (enExample)
PH (1) PH12014502551B1 (enExample)
PL (1) PL2849798T3 (enExample)
PT (1) PT2849798T (enExample)
RS (1) RS62030B1 (enExample)
SG (1) SG11201407599SA (enExample)
SI (1) SI2849798T1 (enExample)
SM (1) SMT202100319T1 (enExample)
TW (1) TWI635864B (enExample)
WO (1) WO2013170386A1 (enExample)
ZA (1) ZA201408674B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
EP2890403A4 (en) * 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
RS64833B1 (sr) * 2014-07-10 2023-12-29 Replicor Inc Helatni fosforotioatni polimeri nukleinske kiseline za upotrebu u kombinaciji sa inhibitorom hbv polimeraze za lečenje virusnih infekcija hepatitisa b i hepatitisa d
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
MX2021005357A (es) * 2018-11-08 2021-06-30 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
JP2005538186A (ja) * 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2007036016A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
EP2229459B1 (en) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2512491B1 (en) * 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
KR20150039873A (ko) * 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
EP2890403A4 (en) 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS

Also Published As

Publication number Publication date
IL235548B (en) 2019-07-31
CL2014003134A1 (es) 2015-02-13
RS62030B1 (sr) 2021-07-30
PH12014502551B1 (en) 2019-10-11
CY1124345T1 (el) 2022-07-22
CO7131387A2 (es) 2014-12-01
TWI635864B (zh) 2018-09-21
PT2849798T (pt) 2021-05-18
MY168778A (en) 2018-12-04
TW201408308A (zh) 2014-03-01
NZ703095A (en) 2016-07-29
HUE054875T2 (hu) 2021-10-28
US9492506B2 (en) 2016-11-15
ZA201408674B (en) 2016-01-27
CN104349793A (zh) 2015-02-11
HRP20210840T1 (hr) 2021-08-06
KR20150013309A (ko) 2015-02-04
EP2849798A1 (en) 2015-03-25
PL2849798T3 (pl) 2021-10-18
JP2015517504A (ja) 2015-06-22
EA035967B1 (ru) 2020-09-07
HK1204279A1 (en) 2015-11-13
AU2013262416A1 (en) 2014-12-18
BR112014028654A2 (pt) 2017-10-10
EA201401278A1 (ru) 2015-04-30
CN104349793B (zh) 2017-11-10
SMT202100319T1 (it) 2021-09-14
EP2849798B1 (en) 2021-04-07
DOP2014000264A (es) 2015-01-31
EP2849798A4 (en) 2016-03-09
ECSP14027694A (es) 2015-12-31
CA2873529C (en) 2020-08-18
MX346239B (es) 2017-03-13
IL235548A0 (en) 2015-01-29
PH12014502551A1 (en) 2015-01-21
LT2849798T (lt) 2021-08-10
DK2849798T3 (da) 2021-05-31
ES2873844T3 (es) 2021-11-04
WO2013170386A1 (en) 2013-11-21
CA2873529A1 (en) 2013-11-21
US20130309201A1 (en) 2013-11-21
MX2014014021A (es) 2015-02-10
CR20140527A (es) 2014-12-15
SI2849798T1 (sl) 2021-08-31
KR102068109B1 (ko) 2020-01-21
AU2013262416B2 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201807912SA (en) Vaccine against rsv
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201408261UA (en) Syringe
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407261XA (en) Oligonucleotide chelate complex methods
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments